Lataa...
ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation?
BCR-ABL1 transcripts at imatinib cessation were quantified by ddPCR for 175 patients on the STIM2 trial. Patients with BCR-ABL1 transcripts below a defined cut-off had a twelve-month molecular recurrence rate of 46% versus 68% for those above the cut-off. Implications of using ddPCR in forecasting s...
Tallennettuna:
| Julkaisussa: | Clin Cancer Res |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6858959/ https://ncbi.nlm.nih.gov/pubmed/31540978 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-2270 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|